Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research presented at the American College of Cardiologys Annual Scientific Session (ACC.25) and simultaneously published in JACC
This occurs because both drugs slow down digestion and communicate with the brain to reduce appetite
Shah agrees
Correspondencia: Dra
2025;3:1008132 DOI: Received: September 03, 2025 Accepted: September 23, 2025 Published: October 30, 2025 Academic Editor: Alessandra Tolomelli, University of Bologna, Italy The article belongs to the special issue Innovative Therapeutics in Hepato-Gastroenterology Metabolic dysfunction-associated steatohepatitis (MASH) is emerging as a leading cause of cirrhosis, hepatocellular carcinoma, and liver-related mortality worldwide
